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The healthcare system in Korea provides coverage to all the people who are residing in Korea, so
the data of the Korea healthcare system are national-wide and relatively accurate. We obtained the
recent 5-year data (2004–2008) on the treatment of BPH from the national health insurance system.
We tried to determine the trends or changes of BPH treatments in Korea. Over 3.8 million men
visited clinics and were prescribed one or more BPH medications, and more than 44000 men
underwent surgical treatment during 2004–2008. Compared with the year 2004, two times the
patients were prescribed BPH medications in 2008. With respect to the surgical treatment, the
number of cases was increased 1.6 times in 2006 compared with the previous years. The most
commonly used surgical option was TURP before 2006, but laser therapy was carried out as much as
TURP in 2006 and in the following years. The relative risk of laser therapy in the 50s is 1.53 (95% CI
is 1.47–1.59). In conclusion, our national-wide data for the Korean BPH patients show that these
patients’ medical treatment increased during the 5 years from 2004 to 2008. Laser treatment had
increased and it might replace TURP in several years.
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Introduction
BPH is defined clinically as a condition that is character-
ized by the combination of an enlarged prostate and
lower urinary tract symptoms (LUTS). These symptoms
are variable and can have a significant negative impact
on the quality of life, leading many men to seek a
physician.
1
In the United States, B4.5 million visits were made
to physicians’ offices for a primary diagnosis of BPH
and almost 8 million visits were made with a primary
or secondary diagnosis of BPH.
2 In Korea, the preva-
lence of clinical BPH in a community-base study of
Chungbuk province was 27.7%, using the definition
of BPH that combined a prostate volume X20cm
3 and
IPSS X8.
3
Medical treatment is thought to be first-line therapy in
men with symptomatic BPH.
4 Several alpha blockers and
5 alpha reductase inhibitors are widely used for
treatment of BPH. As for surgical treatment, TURP was
gold standard, but laser prostatectomy showed compar-
able results to conventional TURP.
5 But there is no
recently published data of whole national-wide investi-
gation about treatment of BPH.
The healthcare system in Korea provides coverage to
all its citizens and it is comprehensively managed in the
form of social insurance. It has two components, health
insurance and medical aid, which is free medical care for
the lower-income groups. The former is funded by
beneficiaries’ contributions according to their incomes
and the latter is funded by general revenue. Therefore
the data of the Korea healthcare system are national wide
and relatively accurate as compared with other re-
sources. We obtained the recent 5-year data of BPH
treatment courtesy of the Health Insurance Review and
Assessment Service (HIRA) in Korea.
We analyzed the medical and surgical treatments
for the Korean BPH patients from HIRA data. We tried
to determine that what age group was most rapidly
increased in visiting physicians for treatment of BPH
and whether there are any trends or changes of BPH
treatments during 5 years. And we also assessed whether
laser therapy was conducted as many as TURP after
being introduced in Korean insurance system.
Materials and methods
This study was exempted from evaluation by the
institutional review board of the Boramae medical center.
We obtained the data from 2004 to 2008 from the
HIRA. The data of the code N40, which indicate BPH,
from the National Center for Health Statistics Inter-
national Classification of Diseases, 9th revision (ICD-9)
was included. It contained various parameters: the year,
age and regions where the men had visited to the clinic,
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www.nature.com/pcanthe medication categories they had been prescribed and
the surgical treatment they had received. Age was
divided by decades, and the regions were divided into
seven metropolises, including Seoul, and nine provinces
by administrative divisions of Korea. Each province
included several small cities and rural areas. Four kinds
of drugs such as alpha-blockers, 5 alpha-reductase
inhibitors, anti-cholinergics and antidiuretics are currently
being used in Korea. Alpha-blockers included alfuzosin
ER (extended release), doxazocin gastrointestinal thera-
peutic system, tamsulosin and terazosin, the 5 alpha
reductase inhibitors were dutasteride and finasteride, and
the anti-cholinergics were flavoxate, oxybutynin XL,
propiverine and tolterodine ER. The available antidiuretic
was only one formulation called desmopressin.
Nocturia is one of most bothersome symptoms in
patients with BPH and can have a marked impact on
quality of life. In some study, alpha-blocker monotherapy
resulted in both a subjective and objective improvement
of nocturia in men with LUTS.
6 Oral desmopressin had
effects in patients with BPH especially for nocturnal
polyuria.
7 So desmopressin was included for medical
treatment modality in our study.
Four kinds of surgeries were included in our data: TURP,
open prostatectomy, hyperthermia and laser therapy.
Hyperthermia therapy of the prostate included transure-
thral needle ablation (TUNA), Prostron, Thermex, Micro-
focus, Prosta and so on. Laser therapy of the prostate was
mainly KTP photoselective vaporization of the prostate.
The number of each surgical case and the number of
patients received BPH medication were analyzed using
Poisson’s regression model, respectively. Relative risks of
the surgical cases were estimated by year and age from
each surgical treatment. The relative risk (RR) of the
number of patient received BPH medication by year was
estimated, which was adjusted by age, drug, clinic and
region. The RRs were obtained by taking the exponential
of the parameter estimates in the Poisson’s models. The
significance of the RRs was determined using the Wald
test statistic by using the estimated variance-covariance
matrix. A significance of interaction between two
significant factors in any Poisson’s model was tested.
All hypotheses were evaluated in a two-sided manner,
and P-values of o0.05 were considered significant.
Results
More than 760000 men annually visited medical facilities
and they were prescribed medications for BPH, and
more than 44000 men underwent surgical treatment such
as TURP, open prostatectomy, hyperthermia and laser
therapy in 2004–2008. For the 5 years, over 3.8 million
men visited health care centers and were prescribed one
or more BPH medication. The number of patients who
were prescribed BPH medications in 2008 was increased
almost two times compared with that in 2004 (Table 1). In
their 30s, there is no annual increase in the number of
patients who were prescribed BPH medications. The
BPH medications were categorized as alpha-blockers, 5
alpha reductase inhibitors, anti-cholinergics and anti-
diuretics. The numbers of patients who were prescribed
BPH medications of the first three categories were
increased two times in 2008 as compared with that in
2004. And antidiuretics such as desmopressin were used
14 times more in 2008 as compared with that in 2004
(Table 2).
After a Poisson’s regression analysis, we found that
BPH medications were depending on age groups, years
(Po0.0001). Poisson’s regression analysis showed that
the interaction between age and study year was
significant (Po0.0001). It means that the variation of
BPH medications by years was significantly different
depending on the age groups. The estimated RR is
shown in Figure 1. In the age of 70s, the number of
patients was most rapidly increased compared with
previous year. The RRs of alpha-blockers were 1.0297
(95% CI: 1.0291–1.0302), 1.1448 (95% CI: 1.1447–1.1.1449),
1.1666 (95% CI: 1.1666–1.1666), 1.1596 (95% CI: 1.1596–
1.597), 1.222 (95% CI: 1.2220–1.2221) and 1.1831 (95% CI:
1.1830–1.1832) in their 30s, 40s, 50s, 60s, 70s and 80s,
respectively.
With respect to the surgical treatments, the number
of cases was increased 1.6 times in 2006 compared
with the previous years, and a similar number of cases
was maintained in the following years. The most
commonly used surgical option was TURP before 2006,
but laser therapy such as photoselective vaporization
was carried out as much as TURP in 2006 and in the
following years (Table 3). In Korea, laser therapy of BPH
was not under coverage of medical insurance system
before 2006, so our data showed that laser therapy was
not conducted until 2005. Among the age groups, the
patients in their 60s most often underwent surgical
treatment (Table 3), but patients in their 70s showed
most rapid increase in receiving surgical treatment
(Table 4). The RRs of TURP were 1.0472 (95% CI:
0.9392–1.1675), 1.0319 (95% CI: 0.9998–1.0650), 0.9962
(95% CI: 0.9812–1.0114), 1.0867 (95% CI: 1.0690–1.1046)
and 1.0753 (95% CI: 1.0412–1.1105) in their 40, 50, 60, 70
and 80s, respectively, compared with the previous year.
And those who underwent laser therapy increased 1.53
times in their 50s compared with the previous year
(Table 4).
Discussions
The National Health Insurance (NHI) program of Korea
covers all the people who are residing in the territory of
Table 1 Numbers of patients, according to the age groups, who were prescribed BPH medications during the 5 years
Age group 30s(%) 40s(%) 50s(%) 60s(%) 70s(%) 80s(%) Total
Year No. of patients
2004 7452 (1.4) 38717 (7.5) 109791 (21.2) 198317 (38.4) 125934 (24.4) 36879 (7.1) 517090
2005 8095 (1.3) 44893 (7.2) 133688 (21.3) 235604 (37.5) 159681 (25.4) 45664 (7.3) 627625
2006 8573 (1.1) 55793 (7.1) 170894 (21.8) 288784 (36.9) 202798 (25.9) 55917 (7.2) 782759
2007 7662 (0.9) 60864 (6.7) 192628 (21.2) 333240 (36.7) 246426 (27.1) 67372 (7.4) 908192
2008 7649 (0.8) 64827 (6.3) 212791 (20.5) 376543 (36.3) 294096 (28.4) 80158 (7.7) 1036064
Data from national health insurance program
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insurance system, its main sources of finance are
contributions from the insured and government subsidy.
It took just 12 years for the Korean government to
achieve universal coverage after the implementation of a
mandatory medical insurance program for workplaces
with 500 employees or more in 1977. The Minister of
Health and Welfare oversees the national health insur-
ance system. The National Health Insurance Corporation
(NHIC) serves as the insurer and the HIRA conducts
reviews and assessment of medical fees. ‘Fee for Service’
has been the traditional reimbursement system. As a
single payer, the NHIC is responsible for the NHI
program’s operation and management.
The NHI system has greatly contributed to improving
the quality of life of the public by ensuring low-cost
access to healthcare. As a result, Korean society has
enjoyed much better health outcomes in terms of life
expectancy and infant mortality. According to the
National Statistical Office of Korea, life expectancy in
2010 is expected to average 79 years, ranking 22nd in the
world. NHI covers all the people, even foreign workers,
who are residing in Korea. So the data from the NHI are
national wide and more accurate than any other data.
BPH is the non-malignant enlargement of the prostate
gland. Clinically, BPH leads to voiding dysfunction,
which is most often referred to LUTS.
8 BPH and LUTS
are common in men 40 years or older and they increase
with age. In 2000, the number of outpatient visits for
BPH was 14473/100000 from the data of the Urologic
Diseases in America BPH project.
2 Approximately 4.5
million visits were made to physician offices for a
primary diagnosis of BPH and almost 7.7 million visits
were made with a primary or secondary diagnosis of
BPH in 2000.
2 According to that report, there was more
than a 1.5-fold increase in the number of outpatients’
visits in 2000 compared with 1994. According to our data,
over 1 million patients were prescribed BPH medications
in 2008, and there was almost a two times increase
compared with that in the year 2004. This was thought to
be because of Korea’s specific situation such as the rapid
change to an aged society, the westernization of eating
habits and so on. According to the National Statistical
Office of Korea, the population of those aged 65 or older
increased by 33 percent to about 4.36 million, only 5
years after it first exceeded 3 million. At this pace,
Korean society is expected to become a so-called ‘aged
society’ by 2013, only 13 years after its designation as an
‘aging society’ in 2000. It is more rapid than that of other
countries such as France, the US and even Japan.
Table 3 Numbers of patients, according to the surgical option and
age groups, who underwent surgical treatment during the 5 years
TURP Open prostatectomy Hyperthermia Laser
Year
2004 3754 179 2596 0
2005 3694 169 2574 0
2006 3959 192 1959 4083
2007 3980 142 1709 4605
2008 4398 145 2022 4191
Age group
30s 16 0 216 21
40s 163 3 1674 411
50s 1933 37 3236 2521
60s 8326 330 3702 5810
70s 7509 367 1733 3549
80s 1838 90 299 567
Total 19785 827 10860 12879
Table 4 Estimated RRs of surgical modalities compared with
previous year by Poisson’s analysis
RR Wald 95% confidence limits P-value
TURP
40s 1.0472 0.9392 1.1675 0.4062
50s 1.0319 0.9998 1.065 0.0515
60s 0.9962 0.9812 1.0114 0.6237
70s 1.0867 1.069 1.1046 o0.0001
80s 1.0753 1.0412 1.1105 o0.0001
Open prostatectomy
Whole age
a 0.9448 0.9001 0.9916 0.0215
Hyperthermia
40s 0.9439 0.9124 0.9765 0.0009
50s 0.9448 0.922 0.9681 o0.0001
60s 0.9119 0.8913 0.933 o0.0001
70s 0.864 0.8353 0.8936 o0.0001
80s 0.6813 0.6241 0.7439 o0.0001
Laser
40s 1.0486 0.9315 1.1805 0.4317
50s 1.5337 1.477 1.5927 o0.0001
60s 1.0049 0.9736 1.0372 0.7612
70s 1.0296 0.9891 1.0718 0.1542
80s 0.9713 0.8781 1.0744 0.5719
Abbreviation: RRs, relative risks.
aIn open prostatectomy group, interaction between age and study year was
not significant (P¼0.5863), so estimated RR is considered as whole age.
Table 2 Numbers of patients, according to the category of drugs,
who were prescribed BPH medications during the 5 years
Year Alpha-blockers 5ARIs Anticholinergics Antidiuretics
No. of patients
2004 351178 109265 55512 1135
2005 406750 152885 64332 3658
2006 498674 194042 83430 6613
2007 576148 221867 99483 10694
2008 656927 261627 101369 16141
Total 2489677 939686 404126 38241
Abbreviation: ARI, alpha reductase inhibitors.
Figure 1 Estimated relative risks (RRs) of patients number
according to age group, compared with the previous year. ARI,
alpha reductase inhibitors.
Data from national health insurance program
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increase in the prevalence of medical therapy. Contrary
to other age group, prescription of alpha blockers might
be mostly directed to chronic pelvic pain syndrome not
to BPH. So in our national-wide BPH data, annual
prevalence of prescription was about 1% and no increase
in the 30s.
Nocturia is one of the most bothersome symptoms
among LUTS, and has been reported to respond less
satisfactory to treatment than do other LUTS.
9 Nocturnal
polyuria is an important cause of nocturia that may
result from age-related fluctuations in the serum levels of
the antidiuretic hormone arginine vasopressin.
10 Advan-
cing age is also associated with increased nighttime
excretion of water, solutes and electrolytes.
11,12 So, the
synthetic antidiuretic hormone desmopressin is an
effective and well-tolerated treatment for nocturia in
men.
10,13 In Korea, a small clinical trial was reported on
the effects of desmopressin for nocturia in 1999.
14 But it
was not widely used before 2004, because the Korea NHI
system did not permit physicians to prescribe desmo-
pressin for adult nocturia. After permission in 2004, the
number of desmopressin prescriptions has gradually
increased. Desmopressin was used more than 14 times
more often in 2008 as compared with that in 2004, but its
usage was a small portion compared with alpha-blocker
usage.
As for surgical treatment of BPH, laser prostatectomy,
especially photoselective vaporization has steadily
gained clinical utility and become good alternative to
TURP.
15,16
In Korea, laser prostatectomies were increasingly used
for the treatment of BPH since NHI system approved of
photoselective vaporization for the treatment of BPH in
2006. Before 2006, laser prostatectomies were conducted
by some urologists in a few patients. But that data might
be a small portion and were not captured because HIRA
did not reimburse these services, so our data showed that
laser therapy was zero before 2006. In 2007, laser
prostatectomies were conducted more than TURP.
Among the laser prostatectomies, KTP vaporization of
the prostate accounted for the most portion of surgical
treatments. Holmium enucleation of prostate was
approved in 2009 by NHI program of Korea, so laser
prostatectomies would be more frequently carried out
recently. Although conventional KTP was not so good for
large BPH,
17,18 the new modalities such as 120W high
power system and holmiun laser enucleation of the
prostate may overcome, and be preferred option in
huge BPH patients instead of TURP or open prostatect-
omy.
19,20 We think laser prostatectomies might
gradually replace TURP or open prostatectomy in several
years later.
The men in their 60s were most commonly prescribed
BPH medications and they underwent surgery during
the 5 years. That would be explained sociodemographi-
cally that in Korea, the population in their 60s is
larger than the population in both their 70s and the 80s.
The men in their 60s may more actively seek health
care than the other age groups. Some other reports
showed similar results that the men in their 60s more
frequently visited to surgery centers and they com-
plained of more severe LUTS.
2,21
But increase rate was most rapid in the age of 70s both
in medical and surgical treatment. So we think that more
patients in their 70s will be prescribed BPH drug and
undergo BPH surgery in several years later.
Our study has several limitations. Although we
obtained the nation-wide comprehensive data, it lack
the detailed patient information of the BPH status such
as the symptom severity, the co-morbidities and so on.
Complementary alternative medicine such as saw
palmetto is widely used, but it is not under the coverage
of the Korea NHI system. So its data were not included in
our medical treatment data.
In conclusion, our national-wide data for the Korean
BPH patients showed that the patients who received
medical treatment increased during the 5 years. Com-
pared with medical treatments, surgical treatment did
not so much increase. But laser treatment increased and
it might replace TURP in several years in Korea.
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